Profile data is unavailable for this security.
About the company
Convatec Group Plc is a United Kingdom-based medical products and technologies company. The Company is engaged in the development, manufacture and sale of medical products, services, and technologies. It is focused on solutions for the management of chronic conditions. It markets and sells its solutions and services in four categories, such as Advanced Wound Care, Ostomy Care, Continence and Critical Care, and Infusion Care. Advanced Wound Care includes advanced dressings for the management of acute and chronic wounds resulting from ongoing conditions, such as diabetes, and acute conditions resulting from traumatic injury and burns. Ostomy Care includes devices, accessories, and personalized services for individuals with a stoma. Continence and Critical Care includes products and services for people with urinary continence issues related to spinal cord injuries and other causes. Infusion Care includes disposable infusion sets used in insulin pump therapy for people with diabetes.
- Revenue in GBP (TTM)1.66bn
- Net income in GBP100.86m
- Incorporated2016
- Employees10.13k
- LocationConvaTec Group PLC7th Floor, 20 Eastbourne TerraceLONDON W2 6LGUnited KingdomGBR
- Websitehttps://www.convatecgroup.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gerresheimer AG | 1.69bn | 96.92m | 2.85bn | 11.91k | 29.40 | 2.29 | 11.04 | 1.69 | 3.33 | 3.33 | 57.96 | 42.82 | 0.5838 | 4.00 | 6.68 | 171,666.00 | 3.42 | 3.31 | 4.63 | 4.75 | 29.35 | 29.72 | 5.86 | 5.94 | 0.5053 | 4.59 | 0.4425 | 42.68 | 9.54 | 7.79 | 20.81 | 9.00 | 23.42 | 1.68 |
| Sectra AB | 125.00m | 31.04m | 3.10bn | 1.20k | 106.41 | 29.04 | 81.35 | 24.83 | 2.22 | 2.22 | 8.95 | 8.15 | 0.5801 | 24.87 | 1.30 | 1,432,758.00 | 14.41 | 15.75 | 28.61 | 29.52 | 47.24 | 64.95 | 24.83 | 19.59 | 1.56 | -- | 0.0199 | -- | 26.84 | 4.06 | 14.25 | 16.58 | 48.37 | -- |
| Ambu A/S | 572.85m | 41.43m | 3.59bn | 4.75k | 97.87 | 6.42 | 43.22 | 6.26 | 1.38 | 1.38 | 19.09 | 21.05 | 0.7251 | 2.13 | 7.17 | 1,099,437.00 | 5.24 | 3.81 | 5.99 | 4.62 | 57.91 | 59.37 | 7.23 | 5.43 | 1.49 | 16.93 | 0.101 | 22.89 | 7.45 | 12.88 | 80.65 | -13.00 | 6.67 | -- |
| Getinge AB | 2.42bn | 187.17m | 3.82bn | 11.89k | 21.86 | 1.79 | 11.64 | 1.58 | 9.48 | 9.48 | 122.36 | 115.57 | 0.6168 | 2.48 | 7.04 | 2,839,084.00 | 4.81 | 5.31 | 6.35 | 6.98 | 46.27 | 47.83 | 7.79 | 8.69 | 0.6455 | 8.99 | 0.2136 | 37.87 | 12.49 | 5.66 | -3.17 | -- | -0.3944 | 34.49 |
| SCHOTT Pharma AG & Co KgaA | 771.51m | 113.36m | 4.19bn | 4.65k | 37.13 | 6.85 | 25.82 | 5.43 | 0.8899 | 0.8899 | 6.05 | 4.82 | -- | -- | -- | 197,228.20 | -- | -- | -- | -- | 33.96 | -- | 14.73 | -- | 1.00 | -- | 0.1011 | -- | 9.43 | -- | 21.11 | -- | -- | -- |
| Ypsomed Holding AG | 477.36m | 68.21m | 4.63bn | 2.30k | 67.84 | 8.61 | 34.68 | 9.69 | 5.74 | 5.74 | 40.18 | 45.26 | 0.5587 | 5.40 | 4.96 | 238,875.00 | 7.98 | 4.41 | 12.40 | 6.81 | 34.47 | 27.26 | 14.29 | 7.38 | 0.5967 | 20.89 | 0.293 | 20.50 | 10.25 | 3.86 | 52.83 | 5.44 | 8.64 | 29.46 |
| Carl Zeiss Meditec AG | 1.74bn | 219.94m | 4.72bn | 4.95k | 21.41 | 2.68 | -- | 2.72 | 2.93 | 2.93 | 23.12 | 23.41 | 0.7296 | 1.81 | 5.57 | 427,523.50 | 9.27 | 9.56 | 11.33 | 11.72 | 56.32 | 57.84 | 12.70 | 13.15 | 2.41 | -- | 0.1018 | 34.47 | 9.80 | 10.28 | -1.20 | 18.09 | 26.79 | 14.87 |
| DiaSorin SpA | -84.20bn | -84.20bn | 4.80bn | 3.23k | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 10.30 | -- | 11.50 | -- | 66.70 | -- | 21.25 | -- | -- | -- | 24.71 | -15.64 | 11.40 | -33.65 | 0.2167 | 16.49 | -- |
| ConvaTec Group PLC | 1.66bn | 100.86m | 5.17bn | 10.13k | 51.34 | 3.95 | 19.35 | 3.12 | 0.0491 | 0.0491 | 0.8079 | 0.6392 | 0.5865 | 2.57 | 6.14 | 163,720.50 | 3.57 | 2.36 | 4.18 | 2.73 | 56.04 | 55.03 | 6.08 | 4.34 | 0.8835 | 2.65 | 0.4367 | 127.29 | 3.37 | 3.18 | 107.15 | -6.93 | 12.37 | 31.41 |
| Amplifon SpA | 1.93bn | 135.31m | 5.67bn | 14.38k | 41.71 | 5.92 | 15.44 | 2.94 | 0.7137 | 0.7137 | 10.16 | 5.03 | 0.6183 | 20.30 | 10.56 | 159,464.60 | 4.34 | 4.31 | 6.35 | 5.81 | 23.78 | 59.01 | 7.03 | 7.28 | 0.4667 | 5.98 | 0.5814 | 34.26 | 6.65 | 10.66 | -12.21 | 9.08 | 12.68 | 15.68 |
| Demant A/S | 2.53bn | 288.06m | 6.46bn | 21.62k | 22.65 | 6.17 | -- | 2.55 | 11.44 | 8.05 | 100.58 | 41.97 | 0.7431 | 2.05 | 5.88 | 1,037,923.00 | 8.46 | 8.27 | 12.20 | 13.23 | 73.72 | 74.14 | 11.38 | 11.34 | 0.9529 | 5.98 | 0.6075 | 0.00 | 13.89 | 10.00 | 12.23 | 6.96 | 8.80 | -- |
| Holder | Shares | % Held |
|---|---|---|
| Artisan Partners LPas of 31 Dec 2022 | 97.98m | 4.78% |
| Black Creek Investment Management, Inc.as of 15 May 2024 | 97.82m | 4.77% |
| Capital Research & Management Co. (Global Investors)as of 31 Dec 2022 | 97.42m | 4.75% |
| Schroder Investment Management Ltd.as of 01 Jul 2024 | 59.59m | 2.91% |
| The Vanguard Group, Inc.as of 01 Jul 2024 | 57.02m | 2.78% |
| Massachusetts Financial Services Co.as of 01 Jul 2024 | 47.78m | 2.33% |
| abrdn Investment Management Ltd.as of 31 Dec 2022 | 43.37m | 2.12% |
| FIL Investment Advisors (UK) Ltd.as of 01 Jul 2024 | 42.23m | 2.06% |
| Royal London Asset Management Ltd.as of 01 Jul 2024 | 41.95m | 2.05% |
| BlackRock Investment Management (UK) Ltd.as of 15 May 2023 | 39.63m | 1.93% |
